Immunovant, Inc.
(IMVT - NASDAQ)
28,78 USD
📋 Profilo Aziendale

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

|